In a meta-analysis, there was small advantage of AChE inhibitors over placebo with a modest improvement of 1.72 points on the Neuropsychiatric Inventory (NPI) and 0.03 points on the Alzheimer Disease Assessment Scale, noncognitive (ADAS-noncog) [167]. The gene discussed is ACHE; the disease is Alzheimer disease.